A phase II trial of 43 evaluable patients with ASPS using the anti-PD-L1 atezolizumab showed an ORR of 37.2% with a median duration of response (DOR) of 16.5 months [40]. The gene discussed is CD274; the disease is alveolar soft part sarcoma.